The Swiss drug delivery device maker selected Holly Springs, North Carolina for the location. It plans to invest approximately $249.5 million (CHF 200 million) in the first phase of the plant. It expects the Holy Springs site to supply products for the U.S. market from the end of 2027 onwards.
Expanding in the U.S. widens Ypsomed’s production capacity and helps to strengthen its global partnerships, the company said. To accelerate its expansion, Ypsomed bought a building with 15,000 square meters of space and an option to expand further. It initially plans to create around 100 new jobs, eventually hoping to expand the workforce to around 200 people.
Ypsomed, which sold its diabetes business earlier this year, hopes to drive forward its global growth strategy to meet the increasing global demand for injection systems. This year, it already opened its first manufacturing site in China and expanded a plant in Germany. The company expects to invest further in state-of-the art infrastructure as well as expanding its capacities in Switzerland.
The North Carolina site includes every stage of the supply chain, from R&D to manufacturing, fill/finish and delivery.
“Establishing our new production site in the United States marks an important step in Ypsomed’s global growth strategy. We have deliberately chosen Holly Springs, a location at the heart of our industry, close to our customers. The cooperative approach of the local authorities, the excellent infrastructure, and the proximity to top-tier universities provide ideal conditions for our future growth,” said Simon Michel, CEO of Ypsomed. “This environment will allow us to attract the skilled workforce we need and to further strengthen our position as a leading supplier of self-injection systems worldwide, while contributing to the security of supply for the U.S. healthcare market.”
